NasdaqCM - Nasdaq Real Time Price USD

Mangoceuticals, Inc. (MGRX)

Compare
2.3700 +0.1100 (+4.87%)
At close: November 4 at 4:00 PM EST
2.4600 +0.09 (+3.80%)
Pre-Market: 8:26 AM EST
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
Total Revenue
866.7920
731.4930
8.9390
Cost of Revenue
362.4300
299.9920
4.0890
Gross Profit
504.3620
431.5010
4.8500
Operating Expense
9,408.1270
9,650.3910
1,996.4320
Operating Income
-8,903.7650
-9,218.8900
-1,991.5820
Net Non Operating Interest Income Expense
-229.1510
--
-6.4730
Other Income Expense
--
6.4730
--
Pretax Income
-9,126.4430
-9,212.4170
-1,998.0550
Net Income Common Stockholders
-9,126.0670
-9,212.4170
-1,998.0550
Diluted NI Available to Com Stockholders
-9,126.0670
-9,212.4170
-1,998.0550
Basic EPS
-0.43
-0.57
-0.13
Diluted EPS
-0.43
-0.57
-0.13
Basic Average Shares
21,151.5580
16,113.0290
15,315.0000
Diluted Average Shares
21,151.5580
16,113.0290
15,315.0000
Total Operating Income as Reported
-8,903.7650
-9,218.8900
-1,991.5820
Total Expenses
9,770.5570
9,950.3830
2,000.5210
Net Income from Continuing & Discontinued Operation
-9,126.0670
-9,212.4170
-1,998.0550
Normalized Income
-9,126.0670
-9,212.4170
-1,998.0550
Interest Expense
222.6780
--
6.4730
Net Interest Income
-229.1510
--
-6.4730
EBIT
-8,903.7650
-9,212.4170
-1,991.5820
EBITDA
-8,881.7530
-9,187.5280
-1,987.7190
Reconciled Cost of Revenue
362.4300
299.9920
4.0890
Reconciled Depreciation
22.0120
24.8890
3.8630
Net Income from Continuing Operation Net Minority Interest
-9,126.0670
-9,212.4170
-1,998.0550
Normalized EBITDA
-8,881.7530
-9,187.5280
-1,987.7190
12/31/2022 - 3/21/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers